Safi Biotherapeutics
Safi Biotherapeutics is dedicated to developing on-demand blood cell therapies tailored for individuals in need. As a commercialization partner for a Department of Defense program, the company focuses on overcoming challenges in cell therapy manufacturing, ensuring high consistency and economic viability.
Industries
Nr. of Employees
small (1-50)
Safi Biotherapeutics
Awards
Fiscal Year 2024 Military Prototype Advancement Initiative (MPAI)
Optimization and Standardization of Enhanced Cryo-Storage Capabilities Unique to manufactured Red Blood Cells (mRBCs)
Funding (ceiling)
$3,449,500.63
Award Year
2024
Products
Manufactured red blood cells for transfusion (on-demand)
Red blood cells produced via ex vivo manufacturing intended for acute transfusion (trauma) and tailored transfusions for specific disease indications.
Manufactured red blood cells for transfusion (on-demand)
Red blood cells produced via ex vivo manufacturing intended for acute transfusion (trauma) and tailored transfusions for specific disease indications.
Expertise Areas
- Ex vivo cell therapy manufacturing
- Hematopoietic stem cell expansion
- Bioprocess optimization and scale-up
- Cryopreservation and cryostorage for cell products
Key Technologies
- Blood cell culture and expansion
- Hematopoietic progenitor differentiation protocols
- Bioreactor-based scale-up
- Cryopreservation technologies
Key People
Jon Mogford PhD
Chairman & Co-Founder
Michael Mansour MD, PhD
Co-Founder
Kyle Meetze MBA
COO
Rob Thomas PhD
Scientific Lead
Katie Glen PhD
Lead Biologist
Jon Mogford PhD
Chairman & Co-Founder
Michael Mansour MD, PhD
Co-Founder
Kyle Meetze MBA
COO
Rob Thomas PhD
Scientific Lead
Katie Glen PhD
Lead Biologist
Featured In Technology Showcase
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Investors
J2 Ventures
$5,000,000 funded.
Announced on 2024-09-11.
J2 Ventures
$5,000,000 funded.
Announced on 2024-09-11.
News & Updates
Safi Biotherapeutics has secured funding to enhance its capabilities in growing blood for transfusions.
An article discussing how Safi Biotherapeutics is addressing blood shortages through innovative solutions.
Safi Biotherapeutics has strengthened its position in the market by acquiring EryPharm assets.
A report on technologies developed for effective blood manufacturing in cold weather conditions.
Announcement of the rebranding of Safi Biosolutions to Safi Biotherapeutics.
Safi Biosolutions is working on alternatives to traditional blood donation methods.
Safi Biotherapeutics has secured funding to enhance its capabilities in growing blood for transfusions.
An article discussing how Safi Biotherapeutics is addressing blood shortages through innovative solutions.
Safi Biotherapeutics has strengthened its position in the market by acquiring EryPharm assets.
A report on technologies developed for effective blood manufacturing in cold weather conditions.
Announcement of the rebranding of Safi Biosolutions to Safi Biotherapeutics.
Safi Biosolutions is working on alternatives to traditional blood donation methods.